US OptionsDetailed Quotes
HIMS250103C22000
- 4.60
- +1.60+53.33%
15min DelayClose Jan 3 16:00 ET
4.60High3.85Low
3.85Open3.00Pre Close10 Volume27 Open Interest22.00Strike Price4.23KTurnover5962.62%IV-0.11%PremiumJan 3, 2025Expiry Date4.63Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9726Delta0.0228Gamma5.67Leverage Ratio-74.0903Theta0.0000Rho5.51Eff Leverage0.0000Vega
Hims & Hers Health Stock Discussion
Sign in to post a comment
$Hims & Hers Health (HIMS.US)$ i was stop out when it breaks 25.5 before it went deeper to 24.5 and we have a bounce to 26.6.
When to re enter? when it retest 25.5
What trend is it now? big picture bull, small picture still bear until we break 28.5
Small picture caution - we may go lower to create another LL.
Fundamental remain unchange. Still waiting to see 40-50 TP by 2025
When to re enter? when it retest 25.5
What trend is it now? big picture bull, small picture still bear until we break 28.5
Small picture caution - we may go lower to create another LL.
Fundamental remain unchange. Still waiting to see 40-50 TP by 2025
1
2
$Hims & Hers Health (HIMS.US)$ looks like gonna downtrend more
2
$Hims & Hers Health (HIMS.US)$
Super bullish. Biggest reason to invest in this company in 2025.
Super bullish. Biggest reason to invest in this company in 2025.
2
1
$Hims & Hers Health (HIMS.US)$ those follow my post would hv sold at the top 30 from 25.5 before we drop to 26.56.
Moving to next week, will be tricky. Breaking 25.5 I am closing my position. Its about holding this support line.
Stil hoping to close 30 to hv a more bullish momentum for 2025. But dont hav high expectation on this guys.![]()
Moving to next week, will be tricky. Breaking 25.5 I am closing my position. Its about holding this support line.
Stil hoping to close 30 to hv a more bullish momentum for 2025. But dont hav high expectation on this guys.
6
6
$Hims & Hers Health (HIMS.US)$ Summary
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation.
HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase.
The company is expanding its product offerings and leveraging AI th...
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation.
HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase.
The company is expanding its product offerings and leveraging AI th...
4
$Hims & Hers Health (HIMS.US)$ while last week broader market was red, i hope thats the bottom. We shld see a bounce this shorter trading week.
Those enter to trade at 25.5 this week is the time to unload at 29/30. I expect some resistance and goin back down. Breaking 25.5 i see further downsd to 20.
For investors, staying above 30 EOY I be bullish into 2025. I am optimistic for March 2025 earnings n could create new ATH.
Those enter to trade at 25.5 this week is the time to unload at 29/30. I expect some resistance and goin back down. Breaking 25.5 i see further downsd to 20.
For investors, staying above 30 EOY I be bullish into 2025. I am optimistic for March 2025 earnings n could create new ATH.
3
$Hims & Hers Health (HIMS.US)$ not included or ? 🤔🤨🧐
"GLP-1: Barclays on why 2025 could be an inflection point"
https://uk.investing.com/news/stock-market-news/glp1-barclays-on-why-2025-could-be-an-inflection-point-3849788
"GLP-1: Barclays on why 2025 could be an inflection point"
https://uk.investing.com/news/stock-market-news/glp1-barclays-on-why-2025-could-be-an-inflection-point-3849788
1
1
No comment yet
104248191 : We’re here for the big picture, no worries
一个投机者 : 25 is a good price, not stable now but this company have a great fundamentals